http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
자궁경부암 병기판정 기초검사시 새로운 보조방법으로서 고주파 질식 초음파의 가치
유희석,이은주,장기홍,권혁찬,양정인,김행수,오기석 아주대학교 의과학연구소 1996 아주의학 Vol.1 No.1
To investigate the efficacy of endoluminal ultrasound system (EUS) as a surrogate for high frequency transvaginal ultrasonography and as an optional baseline study in determining parameirial and stromal invasion of early stage cervical cancer, 52 women suspected of cervical cancer underwent EUS. A 12 MHz endoscopic probe was employed to radially scan the cervix for possible lesions suspected to be invasive cancer during a period of 6 months from Feb. 1 to July 1, 1995. Patients also underwent magnetic resonance imaging (MRI) and/or computerized tomography (CT) as a routine mode of baseline study, and were clinically staged by 3 independent physicians specializing in Obstetrics and Gynecology at the Department of Obstetrics and Gynecology, School of Medicine, Ajou University, Suwon, Korea. Thirty one patients subsequently received surgery appropriate for the stage of the disease and the final pathology findings were compared with the results of clinical staging, EUS, MRI/CT by regression analysis. The results showed that there was statistically significant correlation between MRI/CT and pathology (r=0.660, p<0.02), between EUS and pathology (r=0.803, p<0.01), and between clinical staging and pathology (r=0.825, p<0.01). It is concluded that there was significant statistical correlation t>etween EUS, MRI/CT, clinical staging and pathology, but the question remained as to the statistical superiority of EUS over MRI/CT with regard to parametrial invasion and stromal invasion depth assessment. Finally, EUS is useful as an alternative optional diagnostic tool in the baseline study of cervical cancer.
Platinum sensitive 재발성 난소암에서 Carboplatin/Paclitaxel의 효과
장혜진,유희석,임윤경,문세희,장기홍,이정필 대한부인종양 콜포스코피학회 2003 Journal of Gynecologic Oncology Vol.14 No.4
목적 : 재발성 난소암에서 platinum 감수성을 기준으로 2차 항암요법으로 사용한 Carboplatin과 Paclitaxel의 효과를 알아보기 위하여 본 연구를 진행하였다. 연구방법 : 1998년 1월 1일부터 2003년 8월 31일까지 만 5년 8개월 간 아주대학교병원 산부인과에 재발성 난소암으로 입원한 환자 중에서 최초 수술로 난소암을 확진한 후 Cisplatin 또는 Carboplatin 등 platinum 제재가 포함된 항암치료를 받은 후 6개월 이후에 재발한 환자 29명을 대상으로 Carboplatin은 5 AUC를 그리고 Paclitaxel은 175 mg/m^(2)를 투여하였으며, 최소 3회에서 최고 16회까지 투여하였다. 치료효과의 판정은 CT, MRI, Ultrasonography등 영상진단상 암종괴의 크기가 완전히 소실되었을 경우를 완전반응(complete response)으로, 50%이상 감소되었을 경우를 부분반응(partial response)으로, 50% 미만으로 감소되었거나 20% 미만 증가하였을 경우를 불변(stable disease)으로, 그리고 20% 이상 증가되었을 경우를 진행(progressive disease)로 정의하였다. 결과 : 대상 환자에서 완전반응은 6명(21%), 부분반응은 11명(38%), 그리고 불변은 5명(17%)로 전체 반응율 (overall response rate)은 59% 그리고 임상적 유용성(clinical benefit=CR+PR+SD)은 76%이었다. 결론 : 재발성 난소암환자에서 기왕에 사용한 Platinum 제재에 민감한 환자에서는 Carboplatin과 Paclitaxel의 병행 투여가 효과적이었다. Objective : To ascertain the effect of Carboplatin and Paclitaxel combination as a second line regimen for recurrent ovarian carcinoma based on platinum sensitivity. Methods : From January 1st, 1998 through to August 31st, 2003, 29 patients were retrospectively reviewed who had previously underwent primary cytoreductive surgery and adjuvant chemotherapy with Cisplatin or Carboplatin for ovarian carcinoma, and who had later recurred during follow up. All 29 patients had recurred at least 6 months after therapy, and thereafter received second line chemotherapy consisting of Carboplatin (5 AUC) and Paclitaxel (175 mg/㎡) for a minimum of least 3 cycles and a maximum of 16 cycles. Treatment efficacy was assessed by imaging studies including Computerized tomography, Magnetic Resonance Imaging, or Ultrasonography. Complete response was determined as complete disappearance of tumor, partial response at least than 50% reduction in tumor volume, stable disease as less than 50% reduction or less than 20% increase in tumor volume, and progressive disease as more than 20% increase. Results : There was complete response in 6 (21%) patients, partial response in 11 (38%), stable disease in 5 (17%), showing an overall response rate of 59%. The clinical benefit (CR+PR+SD) was 76%. Conclusion : The combination of Carboplatin and Paclitaxel administration seems to be an effective mode of second line therapy in patients with recurrent ovarian carcinoma who had been sensitive to prior platinum based chemotherapy.
Smooth Muscle Tumor of Uncertain Malignant Potential ( STUMP ) 의 임상적·병리학적 고찰
이희종(Hee Jong Lee),유희석(Hee Sug Ryu),박영한(Young Han Park),주희재(Hee Jae Joo),양성천(Seung Chun Yang),오기석(Kie Suk Oh) 대한산부인과학회 2000 Obstetrics & Gynecology Science Vol.43 No.10
Objective : To evaluate clinical-pathological aspects of smooth muscle tumor of uncertain malignant potential (STUMP), comparing those of leiomyosarcomas and to reclassify them according to the revised classification of smooth muscle tumor, and to investigate the clinical value of new classification.Methods : A retrospective review of clinical and pathological characteristics of 11 cases of STUMP and 7 cases of leiomyosarcoma was done at department of obstetrics and gynecology of Ajou university hospital from 1995 to 1999. They were reclassified according to the revised classification by Kempson and Hendrickson in 1994.Results : Patients' age, parity, status of menopause, history of hormonal use were not significantly different. Vaginal bleeding was most common clinical symptom in both groups(STUMP 55%, leiomyosarcoma 63%) and sarcomatous change was suspected in 1 case of STUMPs and 2 cases of leiomyosarcomas with preoperative transvaginal sonographic examination. Two cases of STUMP were treated with myomectomy only and hysterectomy with or without salpingo-oophorectomy was performed in all cases of leiomyosarcomas and 9 cases of 11 STUMPs. No adjuvant therapy was done and none recurred. Ten cases of STUMP and four cases of leiomyosarcoma were reclassified into leiomyoma with increased mitotic index, one STUMP into atypical leiomyoma, and three leiomyosarcomas remained in the same category by revised classification.Conclusion : Such tumors reclassified into leiomyoma with increased mitotic index showed benign clinical course and the results of this study support new classification. However, atypical leiomyoma with low risk recurrence and smooth muscle tumor with low malignant potential still have possibility of malignant clinical course.